Eugene L. Chang Partner MAIN OFFICE: New York Willkie Farr & Gallagher LLP 787 Seventh Avenue New York, N.Y. 10019-6099, U.S.A. T 212-728-8988 F 212-728-9988

Eugene L. Chang is a partner in the Intellectual Property and Litigation Departments of Willkie Farr & Gallagher LLP in New York. Mr. Chang specializes in intellectual property litigation and licensing, and the intersection of intellectual property with antitrust and competition law.

Mr. Chang has litigated intellectual property issues in the U.S. and internationally across a wide range of technology areas including software, medical devices, analog and digital circuitry, chemical refrigerants, pharmaceuticals, mechanical systems, optical sensors, and electronic trading systems. He has counseled clients on intellectual property issues arising in private equity transactions, public and private offerings, bankruptcy-related acquisitions and standards-related licensing programs.

Mr. Chang was named to the 2012 BTI Client Service All-Star Team, an elite group of attorneys recognized by leading corporate counsel for delivering superior client service.

Mr. Chang is a Vice Chair of the Asian Practice Committee of the Intellectual Property Owners Association (IPO), and has participated in IPO delegations meeting with judges, officials of various patent offices, and intellectual property organizations in China, Japan and Korea. Mr. Chang has given presentations on Patent Law and Antitrust Law to organizations around the world, and has lectured on U.S. Patent and Antitrust Law at Franklin Pierce Law School in the United States and Fudan University School of Law in China.

Mr. Chang also has strong experience addressing intellectual property issues in renewable energy. He has given presentations on intellectual property topics at renewable energy conferences, including the 24th European Photovoltaic Solar Energy Conference (EUPVSEC) in Hamburg, Germany and the Tenth World Renewable Energy Congress (WREC X) in Glasgow, Scotland. Mr. Chang has also litigated and counseled clients in environmentally friendly technologies such as light emitting diodes (LEDs), compact fluorescent lighting and automotive refrigerants with low global warming potential.

Mr. Chang is also active in pro bono activities and has been honored by the Legal Aid Society of New York with an award for Outstanding Pro Bono Service.

• Lead trial counsel representing GFI Software against three different patent assertion entities in separate patent infringement actions in the Eastern District of Texas. Successfully resolved all three actions on favorable terms
  
  
• Trial counsel successfully representing Hospira Inc. and Orion Corp. in protecting the validity and enforceability of a patent for the active ingredient in the sedative Precedex.
  
  
• Second-chair trial counsel representing a pharmaceutical manufacturer seeking to enforce two patents covering a novel sedative used for intensive care
  
  
• Represented Telcordia Technologies, Inc., Providence Equity Partners and Warburg Pincus in the sale of Telcordia to Ericsson
  
  
• Represented Aquiline Capital in technology investments and acquisitions, including Clear2Pay
  
  
• Represented Insight Venture Partners in multiple transactions, including investment in Drilling Info Inc., the leveraged recapitalization of a German software company, and the sale of Hitwise Inc. to Experian
  
  
• Represented Spheris, Inc. in chapter 11 restructuring proceedings
  
  
• Lead counsel representing a chemical manufacturer in a patent litigation involving automotive refrigerants
  
  
• Successfully represented Philips Medical Systems in enforcing and defending against twenty one patents relating to several different facets of automatic external defibrillator (AED) technology
  
  
• Successfully represented Philips Semiconductors in enforcing patents forming the basis for a successful licensing program covering an industry standard for communication between integrated circuit chips
  
  
• Successfully represented Johnson & Johnson in enforcing pioneering patents relating to coronary stent technology